{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:42:05Z","timestamp":1782603725522,"version":"3.54.5"},"reference-count":27,"publisher":"Baskent University","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.6002\/ect.2020.0479","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T01:47:51Z","timestamp":1614044871000},"page":"304-309","source":"Crossref","is-referenced-by-count":16,"title":["Feasibility of Convalescent Plasma Therapy in Kidney Transplant Recipients With Severe COVID-19: A Single-Center Prospective Cohort Study"],"prefix":"10.6002","volume":"19","author":[{"given":"Akash","family":"Gupta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek B.","family":"Kute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himanshu V.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divyesh P.","family":"Engineer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subho","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pranjal R.","family":"Modi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed J.","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vineet V.","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansy H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Navadiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4021","reference":[{"key":"ref0","unstructured":"1. World Health Organization. Coronavirus disease (COVID-19) Pandemic. Accessed March 24, 2020. https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019"},{"key":"ref1","unstructured":"2. Ministry of Health and Family Welfare, Government of India. Accessed October 15, 2020. https:\/\/www.mohfw.gov.in"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96(5):1048-1050. doi:10.1016\/j.kint.2019.07.012","DOI":"10.1016\/j.kint.2019.07.012"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID\u201019 disease is suspected. Interim guidance 13 March 2020. Accessed April 18, 2020. https:\/\/www.who.int\/publications-detail\/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected","DOI":"10.15557\/PiMR.2020.0003"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020;130(6):2757-2765. doi:10.1172\/JCI138745","DOI":"10.1172\/JCI138745"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020;130(4):1545-1548. doi:10.1172\/JCI138003","DOI":"10.1172\/JCI138003"},{"key":"ref6","unstructured":"7. US Food and Drug Administration. Recommendations for Investigational COVID\u201019 Convalescent Plasma, Content current as of April 13, 2020. Accessed April 18, 2020. https:\/\/www.fda.gov\/vaccines-blood-biologics\/investigational-new-drug-ind-or-device-exemption-ide-process-cber\/recommendations-investigational-covid-19-convalescent-plasma"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. World Health Organization. Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: Interim guidance. Accessed March 13, 2020. https:\/\/www.who.int\/publications-detail\/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected","DOI":"10.15557\/PiMR.2020.0003"},{"key":"ref8","unstructured":"9. National Health Commission of China, Guideline for diagnosis and treatment for novel coronavirus pneumonia. 5th ed. Accessed February 4, 2020. http:\/\/www.nhc.gov.cn\/xcs\/zhengcwj\/202002\/3b09b894ac9b4204a79db5b8912d4440.shtml"},{"key":"ref9","unstructured":"10. Government of Karnataka. Guidelines for COVID-19 convalescent plasma therapy. Accessed June 21, 2020. https:\/\/covid19.karnataka.gov.in"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Chatterjee P. Is India missing COVID-19 deaths? Lancet. 2020;396(10252):657. doi:10.1016\/S0140-6736(20)31857-2","DOI":"10.1016\/S0140-6736(20)31857-2"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Cravedi P, Mothi SS, Azzi Y, et al. COVID-19 and kidney transplantation: results from the TANGO International Transplant Consortium. Am J Transplant. 2020;20(11):3140-3148. doi:10.1111\/ajt.16185","DOI":"10.1111\/ajt.16185"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Bossini N, Alberici F, Delbarba E, et al. Kidney transplant patients with SARS-CoV-2 infection: the Brescia Renal COVID task force experience. Am J Transplant. 2020;20(11):3019-3029. doi:10.1111\/ajt.16176","DOI":"10.1111\/ajt.16176"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507-513. doi:10.1016\/S0140-6736(20)30211-7","DOI":"10.1016\/S0140-6736(20)30211-7"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. D'Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transpl. 2020;26(6):832-834. doi:10.1002\/lt.25756","DOI":"10.1002\/lt.25756"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-1034. doi:10.1016\/S0140-6736(20)30628-0","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"ref16","unstructured":"17. Cheng K, Wei M, Shen H, et al. Clinical characteristics of 463 patients with common and severe type coronavirus disease 2019. Shanghai Med J. 2020:1-15."},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006;145(8):599-609. doi:10.7326\/0003-4819-145-8-200610170-00139","DOI":"10.7326\/0003-4819-145-8-200610170-00139"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect. 2004;10(7):676-678. doi:10.1111\/j.1469-0691.2004.00956.x","DOI":"10.1111\/j.1469-0691.2004.00956.x"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52(4):447-456. doi:10.1093\/cid\/ciq106","DOI":"10.1093\/cid\/ciq106"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357(14):1450-1451. doi:10.1056\/NEJMc070359","DOI":"10.1056\/NEJMc070359"},{"key":"ref21","unstructured":"22. World Health Organization. Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks; updated 2014. Accessed April 18, 2020. https:\/\/www.who.int\/csr\/resources\/publications\/ebola\/convalescent\u2010treatment\/en\/"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Salazar E, Christensen PA, Graviss EA, et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020;190(11):2290-2303. doi:10.1016\/j.ajpath.2020.08.001","DOI":"10.1016\/j.ajpath.2020.08.001"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020;323(16):1582-1589. doi:10.1001\/jama.2020.4783","DOI":"10.1001\/jama.2020.4783"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020;117(17):9490-9496. doi:10.1073\/pnas.2004168117","DOI":"10.1073\/pnas.2004168117"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Naeem S, Gohh R, Bayliss G, et al. Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. Transpl Infect Dis. 2020:e13451. doi:10.1111\/tid.13451","DOI":"10.1111\/tid.13451"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol. 2020;92(9):1475-1483. doi:10.1002\/jmv.25961","DOI":"10.1002\/jmv.25961"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T06:54:09Z","timestamp":1618556049000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/current\/2021\/19\/4\/0\/304\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2020.0479","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}